Avid Bioservices Appoints Pete Gagnon as Vice President of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences

TUSTIN, CA--(Marketwired - May 23, 2016) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM ) ( NASDAQ : PPHMP ), today announced the appointment of Pete Gagnon as the company's vice president of process sciences. As one of the biopharmaceutical manufacturing industry's leading experts and innovators in the purification of biologics, including recombinant proteins, viruses and DNA plasmids, he brings more than 30 years of experience to his new role with Avid. In his new position, Mr. Gagnon's responsibilities will include developing and optimizing innovative technologies for cell culture, purification and analysis, designed to support Avid's expanding manufacturing operations.

Prior to joining Avid, Mr. Gagnon spent 25 years as the founder and president of Validated Biosystems, an international consultancy specializing in hands-on development of biological manufacturing processes. During his time with Validated Biosystems, he worked collaboratively with biotechnology companies around the world to develop and optimize state-of-the-art manufacturing systems built on the latest technologies and capabilities. His work has focused on continuously innovating processes for purifying biologics and has led to the publication of his highly-regarded book, "Purification Tools for Monoclonal Antibodies." Mr. Gagnon is additionally credited with more than 100 scientific journal articles and presentations at major scientific conferences, as well as more than a dozen patents, with an additional 30 pending patent applications, all describing major advances in purification of biologics. Based on his thought leadership in the industry, he also serves as a member of the editorial boards for BioProcess International and Genetic Engineering News and has appeared as a frequent guest editor and reviewer for several top industry journals. Mr. Gagnon just completed a five-year residence in Asia, during which he worked with the Singaporean Agency for Science and Technology to help establish bioprocessing as a major center of excellence within Singapore.

"We are excited to add Pete to the talented team of manufacturing professionals who are driving the impressive and consistent revenue growth that we are experiencing at Avid. He brings unique expertise in high-value manufacturing disciplines that fit nicely with our recently opened state-of-the-art commercial biomanufacturing suite," said Steven W. King, president and chief executive officer of Peregrine Pharmaceuticals and Avid Bioservices. "Specifically, Pete's position as one of the industry's thought leaders in the area of cell line process sciences, which is critical for ongoing innovations in the manufacture of biosimilar products, provide opportunities for the continued growth of our biosimilars manufacturing business. This is one particular area on which we'll be focused with the increased manufacturing capacity made possible by our new facility and we look forward to the contributions that Pete will make."

Mr. Gagnon, who has served as a consultant to Avid since 2004, commented, "I am grateful for the opportunity to join Avid Bioservices on a full time basis. This is an exciting time, marked by revenue growth, facility expansion and an impressive demand for the company's services. Avid is uniquely positioned in the biopharmaceutical contract development and manufacturing sector based on its combination of state-of-the-art manufacturing facilities, equipment and capabilities. That combination of infrastructure and environment gives Avid an outstanding foundation to drive innovation and provide best-in-class services to our current and future clients."

Peregrine recently announced the formal commissioning of its new state-of-the-art commercial biomanufacturing suite in Tustin, California and cGMP production is currently underway. The new 40,000 square foot biomanufacturing facility, which is being operated by Avid Bioservices, is outfitted with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial production of biologics. A range of innovative features are incorporated into the new suite including monolithic modular clean room walls, dedicated support utilities for each key processing area, and the industry's most advanced single-use production systems. Uni-directional process flows separating personnel and materials provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.

About Avid Bioservices Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com .

About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics to stimulate the body's immune system to fight cancer. The company is focused on evaluating its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers. One specific component of this I-O combination strategy includes a planned clinical trial of bavituximab in combination with durvalumab, AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, under a clinical collaboration.

In addition to its drug development programs, Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com .

Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 Email Contact Tim Brons (Media) Vida Strategic Partners 415-675-7402 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

boberdoo Launches Dynamic Consent for Enhanced User Privacy

Updated Category News Views 92

boberdoo's Innovative Approach to One-to-One Consent boberdoo is making waves with its Dynamic Consent solution, a vital tool for businesses looking to comply with the FCC's one-to-one consent regulation. This live solution has been available since May 2024 and is designed to enhance transparency in lead generation by allowing consumers to have a voice in which companies...

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 254

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
Kyocera Unveils Exclusive Knife Set Celebrating 40 Years of Innovation

Updated Category News Views 62

Kyocera celebrated four decades of pushing boundaries in ceramic cutlery, revealing an exclusive two-piece knife set designed for both chefs and home cooks. The knives—a 4.5-inch Utility and a 5.5-inch Santoku—come dressed in vibrant Aegean Blue or Botanical Green and carry a price tag of $85. This limited-edition release is set to hit select retailers by late fall...

Continue Reading
PTC Plans Conference Call for Upcoming Fiscal Q1 Results

Updated Category News Views 145

PTC to Hold Fiscal Q1 Conference Call Boston, January 2026 — PTC (NASDAQ: PTC) is gearing up to unveil its financial performance for the first quarter of fiscal year 2026 on February 4. Investors and interested parties are invited to join a conference call and webcast at 5 PM Eastern Time, right after the stock market closes. This event will provide valuable insights...

Continue Reading
Moke America Unveils Enhanced Electric Street Vehicle for All

Updated Category News Views 282

Introducing the New Electric Street-Legal Moke Moke America, the beloved electric vehicle manufacturer, has taken a bold step forward with the launch of its latest street-legal Moke. Previously classified as a Low Speed Vehicle, this newly upgraded Moke can now reach an impressive top speed of 45 MPH, transforming the driving experience into something truly exhilarating....

Continue Reading